Pharmacology of ADP‐ribosylation

ADP‐ribosyltransferase ARTD1/PARP1 is a target for cancer and ischemia drug development. Several other ARTD‐family enzymes have been characterized in recent years, and it has become clear that their inhibition might also have therapeutic value. This minireview series summarizes current knowledge of...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The FEBS journal 2013-08, Vol.280 (15), p.3542-3542
Hauptverfasser:	Schüler, Herwig, Ziegler, Mathias
Format:	Artikel
Sprache:	eng
Schlagworte:	Adenosine Diphosphate Ribose - metabolism Humans Ischemia - drug therapy Medicin och hälsovetenskap Molecular Targeted Therapy Neoplasms - drug therapy Poly(ADP-ribose) Polymerase Inhibitors Poly(ADP-ribose) Polymerases - metabolism Protein Processing, Post-Translational - drug effects
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	ADP‐ribosyltransferase ARTD1/PARP1 is a target for cancer and ischemia drug development. Several other ARTD‐family enzymes have been characterized in recent years, and it has become clear that their inhibition might also have therapeutic value. This minireview series summarizes current knowledge of pharmacological inhibition of ADP‐ribosyltransferases by a compound class called PARP inhibitors and the prospects for drug development.
ISSN:	1742-464X 1742-4658 1742-4658
DOI:	10.1111/febs.12388